Literature DB >> 31045667

Multiflora and Gram-Negative Microorganisms Predominate in Infections Affecting Pelvic Endoprostheses Following Tumor Resection.

P T J Sanders1, M P A Bus1, H Scheper1, R J P van der Wal1, M A J van de Sande1, J A M Bramer2, G R Schaap2, M G J de Boer1, P D S Dijkstra1.   

Abstract

BACKGROUND: Periprosthetic infections after pelvic reconstruction are common, with reported rates ranging from 11% to 53%. Management of these infections is troublesome, as they commonly necessitate multiple surgical interventions and implant removal. The epidemiology and outcomes of these infections are largely unknown. The aim of this study was to analyze the causative microorganisms and the clinical outcome of treatment in a series of patients with pelvic endoprostheses affected by infection following tumor resection.
METHODS: In this retrospective, multicenter cohort study, we identified all patients who developed an infection after endoprosthetic reconstruction in periacetabular tumor resection, between 2003 and 2017. The microorganisms that were isolated during the first debridement were recorded, as were the number of reoperations for ongoing infection, the antimicrobial treatment strategy, and the outcome of treatment.
RESULTS: In a series of 70 patients who underwent pelvic endoprosthetic reconstruction, 18 (26%) developed an infection. The type of pelvic resection according to the Enneking-Dunham classification was type P2-3 in 14 (78%) of these patients and type P2 in 4 (22%). Median follow-up was 66 months. Fourteen (78%) of the 18 patients with infection had a polymicrobial infection. Enterobacteriaceae were identified on culture for 12 (67%). Of a total 42 times that a microorganism was isolated, the identified pathogen was gram-negative in 26 instances (62%). Microorganisms associated with intestinal flora were identified 32 times (76%). At the time of latest follow-up, 9 (50%) of the patients had the original implant in situ. Of these, 2 had a fistula and another 2 were receiving suppressive antibiotic therapy. In the remaining 9 (50%) of the patients, the original implant had been removed. At the time of final follow-up, 3 of these had a second implant in situ. The remaining 6 patients had undergone no secondary reconstruction.
CONCLUSIONS: Infections that affect pelvic endoprostheses are predominantly polymicrobial and caused by gram-negative microorganisms, and may be associated with intestinal flora. This differs fundamentally from mono-bacterial gram-positive causes of conventional periprosthetic joint infections and may indicate a different pathogenesis. Our results suggest that prophylaxis and empiric treatment may need to be re-evaluated. LEVEL OF EVIDENCE: Therapeutic Level IV. See Instructions for Authors for a complete description of levels of evidence.

Entities:  

Mesh:

Year:  2019        PMID: 31045667     DOI: 10.2106/JBJS.18.00836

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  4 in total

Review 1.  Imaging following surgery for primary appendicular bone tumours.

Authors:  Imran Khan; Craig Gerrand; Asif Saifuddin
Journal:  Skeletal Radiol       Date:  2021-01-22       Impact factor: 2.199

2.  Letter to the Editor: Disruption of the Gut Microbiome Increases the Risk of Periprosthetic Joint Infection in Mice.

Authors:  Lukasz Pulik; Nina Grabowska; Mateusz Olbrys; Karolina Gorecka; Pawel Legosz
Journal:  Clin Orthop Relat Res       Date:  2021-04-01       Impact factor: 4.176

Review 3.  Antimicrobial Prophylaxis for the Prevention of Surgical Site Infections in Orthopaedic Oncology - A Narrative Review of Current Concepts.

Authors:  Daniel Müller; Dominik Kaiser; Kati Sairanen; Thorsten Studhalter; İlker Uçkay
Journal:  J Bone Jt Infect       Date:  2019-10-15

4.  A Short-Course Antibiotic Prophylaxis Is Associated with Limited Antibiotic Resistance Emergence in Post-Operative Infection of Pelvic Primary Bone Tumor Resection.

Authors:  Yoann Varenne; Stéphane Corvec; Anne-Gaëlle Leroy; David Boutoille; Mỹ-Vân Nguyễn; Sophie Touchais; Pascale Bémer; Antoine Hamel; Denis Waast; Christophe Nich; François Gouin; Vincent Crenn
Journal:  Antibiotics (Basel)       Date:  2021-06-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.